ESR1 and breast cancer: One of the biggest challenges for BC treatment is its heterogeneity, exemplified by BC subtypes that show a high diversity of genetic and epigenetic origins, which determine its classification and treatment and are directly related to the state of relevant receptors such as estrogen receptor (ER), progesterone receptor (PR), and human epithelial receptor 2 (HER2) [2].